Cardiology
Perioperative Cardiac Risk Assessment
ESC 2022 — Revised Cardiac Risk Index, functional capacity, biomarkers, decision on further testing and beta-blocker / statin / antiplatelet management.
Source: ESC 2022 Non-Cardiac Surgery; ACC/AHA 2014
Step 1 of ~6
info
Risk Stratification Components
Integrate: surgical risk (low <1%, intermediate 1–5%, high >5% MACE), patient cardiac risk factors (RCRI), functional capacity (METs), biomarkers (NT-proBNP, hs-troponin).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Labetalol (IV — Hypertensive Emergency) · Combined Alpha-1 and Beta-Adrenergic Blocker
- Metoprolol (IV/Oral — Cardiology) · Beta-Blocker
- Carvedilol · Beta-Blocker / HFrEF
- Acebutolol · Beta-blocker
- Sotalol hydrochloride · Class III antiarrhythmic + non-selective β-blocker
- Esmolol hydrochloride · Cardioselective beta-blocker (ultra-short-acting)
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only. Always apply local guidelines and clinical judgement.